The Latest Breaking News from Boston Scientific

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

As Boston Scientific has outpaced the S&P 500 Index over the past year, analysts are strongly optimistic about the stock’s prospects.

Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.

The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE:BSX) ENDOTAK RELIANCE defibrillation leads, following a letter from the company alerting healthcare providers of possible reduced shock efficacy.

U.S. health officials have issued warnings on two separate Boston Scientific heart devices recently linked to injuries and deaths

Stronger‑than‑expected sales and raised full‑year guidance underscore Boston Scientific Corporation‘s (NYSE:BSX) momentum—and hint at where its next product wins may come.

BSX stock may extend its solid performance as options activity and historical patterns suggest a bullish setup with favorable short-term odds.

Boston Scientific is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings growth.

Due to Boston Scientific's strong performance relative to its industry peers over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Boston Scientific has outpaced the broader market over the past year and analysts are highly upbeat about its future prospects.

A years-long wait for compensation continues for women injured from pelvic mesh implants with delays blamed on difficulty in obtaining medical records.